Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era.

Fletcher CD, Kahl BS.

Leuk Lymphoma. 2014 Oct;55(10):2228-40. doi: 10.3109/10428194.2013.869326. Epub 2014 Feb 24. Review.

PMID:
24286262
2.

Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.

Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, Vignati A, Scarfò L, Sassone M, Govi S, Caligaris-Cappio F.

Br J Haematol. 2015 Mar;168(5):654-62. doi: 10.1111/bjh.13194. Epub 2014 Oct 14.

PMID:
25312994
3.

Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.

Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, Quek R, Tao M, Lim ST.

Ann Hematol. 2011 Jul;90(7):809-18. doi: 10.1007/s00277-010-1150-7. Epub 2011 Jan 13.

PMID:
21229246
4.

Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.

Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R.

Br J Haematol. 2012 Oct;159(1):39-49. doi: 10.1111/j.1365-2141.2012.09247.x. Epub 2012 Jul 31. Review.

PMID:
22849793
5.

Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.

Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA.

Cancer. 2012 Jun 1;118(11):2944-51. doi: 10.1002/cncr.26588. Epub 2011 Oct 17.

6.

Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse.

Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ.

Haematologica. 2011 Jul;96(7):1002-7. doi: 10.3324/haematol.2011.041277. Epub 2011 Apr 12.

7.

Central nervous system prophylaxis in diffuse large B-cell lymphoma.

Zahid MF, Khan N, Hashmi SK, Kizilbash SH, Barta SK.

Eur J Haematol. 2016 Aug;97(2):108-20. doi: 10.1111/ejh.12763. Epub 2016 May 25. Review.

PMID:
27096423
8.

Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era?

Deng L, Song Y, Zhu J, Zheng W, Wang X, Xie Y, Lin N, Tu M, Ping L, Ying Z, Liu W, Zhang C.

Int J Hematol. 2013 Dec;98(6):664-71.

PMID:
24234713
9.

Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.

Zhang J, Chen B, Xu X.

Leuk Lymphoma. 2014 Mar;55(3):509-14. doi: 10.3109/10428194.2013.811239. Epub 2013 Jul 29. Review.

PMID:
23741977
10.

Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.

Ghose A, Kundu R, Latif T.

Crit Rev Oncol Hematol. 2014 Sep;91(3):292-303. doi: 10.1016/j.critrevonc.2014.02.006. Epub 2014 Mar 12. Review.

PMID:
24698003
11.

Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.

Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP.

Cancer. 2010 Sep 15;116(18):4283-90. doi: 10.1002/cncr.25278.

12.

[Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].

Shimada K.

Brain Nerve. 2011 May;63(5):467-72. Review. Japanese.

PMID:
21515926
13.

Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era.

Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Hatta Y, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Ishigatsubo Y, Takeuchi K.

Cancer Sci. 2012 Feb;103(2):245-51. doi: 10.1111/j.1349-7006.2011.02139.x. Epub 2011 Nov 29.

14.

Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.

Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M.

Ann Oncol. 2013 May;24(5):1385-92. doi: 10.1093/annonc/mds621. Epub 2012 Dec 17.

PMID:
23247661
15.

Prevention of CNS relapse in diffuse large B-cell lymphoma.

Kridel R, Dietrich PY.

Lancet Oncol. 2011 Dec;12(13):1258-66. doi: 10.1016/S1470-2045(11)70140-1. Epub 2011 Sep 18. Review.

PMID:
21933751
16.

First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.

Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E.

J Clin Oncol. 2011 Jul 10;29(20):2766-72. doi: 10.1200/JCO.2010.31.4187. Epub 2011 Jun 6.

17.

[Central nervous system relapse in diffuse large B cell lymphoma: Risk factors].

Sancho JM, Ribera JM; Working Group on Diagnosis, Prevention and Treatment of CNS Infiltration in Patients with DLBCL.

Med Clin (Barc). 2016 Jan 15;146(2):74-80. doi: 10.1016/j.medcli.2014.12.025. Epub 2015 Mar 24. Review. Spanish.

PMID:
25817451
18.

A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.

Cheah CY, Herbert KE, O'Rourke K, Kennedy GA, George A, Fedele PL, Gilbertson M, Tan SY, Ritchie DS, Opat SS, Prince HM, Dickinson M, Burbury K, Wolf M, Januszewicz EH, Tam CS, Westerman DA, Carney DA, Harrison SJ, Seymour JF.

Br J Cancer. 2014 Sep 9;111(6):1072-9. doi: 10.1038/bjc.2014.405. Epub 2014 Jul 29.

19.

[Isolated central nervous system relapse of diffuse large B-cell lymphoma in the era of immunochemotherapy].

Krmek DZ, Ljubić N, Vrbanić L.

Acta Med Croatica. 2012 Dec;66(5):403-7. Croatian.

PMID:
23814970
20.

Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis--A Systematic Review of Prospective Studies.

Ghose A, Elias HK, Guha G, Yellu M, Kundu R, Latif T.

Clin Lymphoma Myeloma Leuk. 2015 Aug;15(8):451-7. doi: 10.1016/j.clml.2015.02.026. Epub 2015 Mar 5. Review.

PMID:
25816933

Supplemental Content

Support Center